RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.4103/ijmpo.ijmpo_33_20
A Brief Review of Treatment Options for Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer
Financial support and sponsorship Nil.![](https://www.thieme-connect.de/media/10.1055-s-00050348/202002/lookinside/thumbnails/10-4103-ijmpo-ijmpo_33_20_247-1.jpg)
The index patient is a 40-year-old female with a strong family history (breast cancer in mother and ovarian cancer in maternal aunt) who presented with a 3-month history of breast lump. On examination, she had a 4 cm breast lump and fixed axillary nodes. Positron-emission tomography-computed tomography reveals no other site of disease. Core biopsy reveals high-grade invasive ductal cancer with triple-negative phenotype. Germ line testing is positive for the pathogenic BRCA1 mutation. She is well-educated and requests you to offer her the best possible treatment that can maximize her chances of cure and minimize her chances of relapse. At the same time, she would not like to go through unnecessary toxicity unless treatment intensification can improve her disease-free survival (DFS)/overall survival (OS).
After carefully considering her requests, you decide to offer her:
-
Four cycles of two-weekly (adriamycin + cyclophosphamide) (AC) followed by four cycles of two-weekly paclitaxel
-
Four cycles of two-weekly AC followed by 12 weeks of weekly paclitaxel
-
Four cycles of two-weekly AC followed by 12 weeks of weekly nanoparticle albumin-bound -paclitaxel
-
Four cycles of two-weekly AC followed by four cycles of paclitaxel with carboplatin
-
Any other.
Triple-negative breast cancer constitutes 15%–20% of all breast cancer cases.[1] These tumors are a heterogeneous group, characterized by the lack of human epidermal growth factor receptor-2 (HER2)/neu, estrogen, and progesterone receptors. The absence of these predictive markers makes chemotherapy the primary treatment option for these tumors. Hence, we must choose a chemotherapy regimen that is most likely to benefit our patients in terms of survival.
The current case represents a scenario often faced in clinical practice. A significant proportion of these patients relapse and most of these relapses are within the 1st year of treatment. It is because of this problem that multiple treatment options have been studied in this select group. We will gradually dissect these options to conclude the best treatment option for the patient in question.
Publikationsverlauf
Eingereicht: 31. Januar 2020
Angenommen: 07. Mai 2020
Artikel online veröffentlicht:
23. Mai 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Gogia A, Raina V, Deo SV, Shukla NK, Mohanti BK. Triple-negative breast cancer: An institutional analysis. Indian J Cancer 2014; 51: 163-6
- 2 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Peto R, Davies C, Godwin J, Gray R, Pan HC. et al. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432-44
- 3 Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM. Dose-dense chemotherapy in nonmetastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 2010; 102: 1845-54
- 4 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: A patient-level meta-analysis of 37-298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440-52
- 5 Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C. et al. SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 2015; 33: 58-64
- 6 Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C. et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): A randomised, phase 3 trial. Lancet Oncol 2016; 17: 345-56
- 7 Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C. et al. NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-Geparsepto. J Clin Oncol 2019; 37: 2226-34
- 8 Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B. et al. Comparing neoadjuvant NAB-paclitaxel vs. paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial: A randomized phase 3 clinical trial. JAMA Oncol 2018; 4: 302-8
- 9 Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I. et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376: 2147-59
- 10 von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 2014; 15: 747-56
- 11 Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM. et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33: 13-21
- 12 Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial. Lancet Oncol 2018; 19: 497-509
- 13 Poggio F, Bruzzone M, Ceppi M, Ponde NF, La Valle G, Del Mastro L. et al. Platinum-based neoadjuvant chemotherapy in triplep-negative breast cancer: A systemic review and meta-analysis. Ann Oncol 2018; 29: 1497-508
- 14 Caramelo O, Silva C, Caramel F, Frutuoso C, Almeida-Santos T. The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple-negative breast cancers-systemic review and meta-analysis. Hered Cancer Clin Pract 2019; 17: 1
- 15 Sikov WM, Polley MY, Twohy E, Perou CM, Singh B, Berry DA. et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). J Clin Oncol 2019; 37: 591
- 16 Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A. et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: Secondary analysis of the geparsixto randomized clinical trial. JAMA Oncol 2017; 3: 1378-85
- 17 Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA. et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol 2018; 29: 2341-7